United Theranostics Parent, LLC (“United Theranostics” or the “Company”), a leader in radiopharmaceutical therapy and supportive molecular imaging for cancer treatment, is pleased to announce the opening of United Theranostics – Princeton.
United Theranostics – Princeton is conveniently located in central NJ in the Forrestal Medical Building, 8 Forrestal Road South, Suite 201, Princeton, NJ, 08540.
United Theranostics – Princeton provides access to cutting-edge radiopharmaceutical therapy and advanced molecular imaging to patients in NJ, PA, NY and Delaware alike. United Theranostics – Princeton is led by Dr. Munir Ghesani, MD, FACNM, FACR, FSNMMI. Dr. Ghesani has practiced in the field of academic nuclear medicine for over 30 years, most recently as the Chief of Nuclear Medicine for Mt. Sinai Hospital in New York. His primary research interests are clinical and translational areas in theranostics, oncologic imaging and radiopharmaceutical therapy. Previous leadership roles include President of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), Chair of the American Board of Nuclear Medicine, Chair of the Government Relations Committee, the FDA Task Force of the SNMMI, and Chair of the Nuclear Medicine and PET Accreditation Committee of the American College of Radiology.
United Theranostics is redefining the practice of nuclear medicine with theranostics for precision cancer care. The Company’s approach lowers the burden on patients undergoing complex innovative radiopharmaceutical therapies through the theranostics integrated imaging/treatment approach – “treat what you see and see what you treat”. United Theranostics clinics utilize advanced radiopharmaceutical therapies and supportive molecular imaging to deliver targeted therapies for patients with various cancers (including metastatic prostate, neuroendocrine and thyroid cancers). The Company also supports the development of new cutting-edge radiopharmaceutical products under investigation for various cancer indications through clinical trials conducted at its clinics.
About United Theranostics
United Theranostics is a national leader in providing cutting-edge radiopharmaceutical therapy and advanced molecular imaging in a comfortable, patient-centric outpatient setting. The Company is dedicated to making personalized theranostics cancer treatment, including clinical trials, accessible to all patients. For more information about United Theranostics, visit https://unitedtheranostics.com/
United Theranostics – Princeton is conveniently located in central NJ in the Forrestal Medical Building, 8 Forrestal Road South, Suite 201, Princeton, NJ, 08540.
United Theranostics – Princeton provides access to cutting-edge radiopharmaceutical therapy and advanced molecular imaging to patients in NJ, PA, NY and Delaware alike. United Theranostics – Princeton is led by Dr. Munir Ghesani, MD, FACNM, FACR, FSNMMI. Dr. Ghesani has practiced in the field of academic nuclear medicine for over 30 years, most recently as the Chief of Nuclear Medicine for Mt. Sinai Hospital in New York. His primary research interests are clinical and translational areas in theranostics, oncologic imaging and radiopharmaceutical therapy. Previous leadership roles include President of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), Chair of the American Board of Nuclear Medicine, Chair of the Government Relations Committee, the FDA Task Force of the SNMMI, and Chair of the Nuclear Medicine and PET Accreditation Committee of the American College of Radiology.
United Theranostics is redefining the practice of nuclear medicine with theranostics for precision cancer care. The Company’s approach lowers the burden on patients undergoing complex innovative radiopharmaceutical therapies through the theranostics integrated imaging/treatment approach – “treat what you see and see what you treat”. United Theranostics clinics utilize advanced radiopharmaceutical therapies and supportive molecular imaging to deliver targeted therapies for patients with various cancers (including metastatic prostate, neuroendocrine and thyroid cancers). The Company also supports the development of new cutting-edge radiopharmaceutical products under investigation for various cancer indications through clinical trials conducted at its clinics.
About United Theranostics
United Theranostics is a national leader in providing cutting-edge radiopharmaceutical therapy and advanced molecular imaging in a comfortable, patient-centric outpatient setting. The Company is dedicated to making personalized theranostics cancer treatment, including clinical trials, accessible to all patients. For more information about United Theranostics, visit https://unitedtheranostics.com/